<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30517257</article-id><article-id pub-id-type="pmc">6257540</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0126</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Combined Off-Pump Coronary Artery Bypass Grafting and Lung Resection
in Patients with Lung Cancer Accompanied by Coronary Artery
Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yeginsu</surname><given-names>Ali</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Vayvada</surname><given-names>Mustafa</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Karademir</surname><given-names>Burcin C.</given-names></name><role>MD</role><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Erk&#x00131;l&#x00131;n&#x000e7;</surname><given-names>Atakan</given-names></name><role>MD</role><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tasci</surname><given-names>Ahmet Erdal</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Buyukbayrak</surname><given-names>Fuat</given-names></name><role>MD</role><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gurcu</surname><given-names>Emre</given-names></name><role>MD</role><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kutlu</surname><given-names>Cemal As&#x00131;m</given-names></name><role>MD</role><xref ref-type="aff" rid="aff6">6</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Thoracic Surgery, Kartal Kosuyolu Yuksek Ihtisas
Training and Research Hospital, Kartal, Istanbul, Turkey.</aff><aff id="aff2">
<label>2</label> Department of Cardiovascular Surgery, Kartal Kosuyolu Yuksek
Ihtisas Training and Research Hospital, Istanbul, Turkey.</aff><aff id="aff3">
<label>3</label> Department of Anesthesia and Reanimation, Kartal Kosuyolu Yuksek
Ihtisas Training and Research Hospital, Istanbul, Turkey.</aff><aff id="aff4">
<label>4</label> Department of Cardiovascular Surgery, Okan University School of
Medicine, Istanbul, Turkey.</aff><aff id="aff5">
<label>5</label> Kartal Kosuyolu Yuksek Ihtisas Training and Research Hospital,
Department of Anesthesia and Reanimation, Istanbul, Turkey.</aff><aff id="aff6">
<label>6</label> Yuzuncu Yil University School of Medicine Gaziosmanpasa Hospital,
Department of Thoracic Surgery, Istanbul, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: Ali Yeginsu, Thoracic Surgery Department,
Kartal Kosuyolu Training and Research Hospital, Cevizli/Kartal, Istanbul,
Turkey, Denizer cd. No:2 34865 &#x02013; Kartal &#x02013; Istanbul, Turkey. E-mail:
<email>yeginsu@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2018</year></pub-date><volume>33</volume><issue>5</issue><fpage>483</fpage><lpage>489</lpage><history><date date-type="received"><day>27</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Optimal surgical approach for the treatment of resectable lung cancer
accompanied by coronary artery disease (CAD) remains a contentious issue. In
this study, we present our cases that were operated simultaneously for
concurrent lung cancer and CAD.</p></sec><sec><title>Methods</title><p>Simultaneous off-pump coronary artery bypass surgery (OPCABG) and lung
resection were performed on 10 patients in our clinic due to lung cancer
accompanied by CAD. Demographic features of patients, operation data and
postoperative results were evaluated retrospectively.</p></sec><sec><title>Results</title><p>Mean patient age was 63.3 years (range 55-74). All patients were male. Six
cases of squamous cell carcinoma, three of adenocarcinoma and one case of
large cell carcinoma were diagnosed. Six patients had single-vessel CAD and
4 had two-vessel CAD. Three patients underwent OPCABG at first and then lung
resection. The types of resections were one right pneumonectomy, three right
upper lobectomies, one right lower lobectomy, three left upper lobectomies,
and two left lower lobectomies. Reoperation was performed in one patient due
to hemorrhage. One patient developed intraoperative contralateral tension
pneumothorax. One patient died due to acute respiratory distress syndrome at
the early postoperative period.</p></sec><sec><title>Conclusion</title><p>Simultaneous surgery is a safe and reliable option in the treatment of
selected patients with concurrent CAD and operable lung cancer.</p></sec></abstract><kwd-group><kwd>Lung Neoplasms</kwd><kwd>Coronary Artery Disease</kwd><kwd>Coronary Artery Bypass, Off-Pump</kwd></kwd-group></article-meta></front><body><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Activated clotting
time</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Lung cancer </td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ARDS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute respiratory
distress syndrome</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LND</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Lymph node
dissection</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LUL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left upper lobe</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery
disease</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MRI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Magnetic resonance
imaging</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OPCABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Off-pump coronary artery
bypass grafting</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DAPT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Dual antiplatelet
therapy</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous coronary
intervention</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ECG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Electrocardiogram</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PET/CT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Positron emission
tomography</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1"> IMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1"> = Internal mammary
artery</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1"> RUL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1"> = Right upper lobe</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>As the elderly population increases, there are an increasing number of patients who
are diagnosed with lung cancer (LC) and have concurrent heart disease requiring
surgical intervention. According to The Society of Thoracic Surgeons database, 20.9%
of the patients undergoing pulmonary resection for LC have coronary artery disease
(CAD); however, only 0.4-0.5% of these patients required coronary artery bypass
grafting (CABG)<sup>[<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>The choice of the ideal surgical procedure is still controversial. Percutaneous
coronary intervention (PCI), followed by lung resection, required months of delay in
tumor management due to the use of dual antiplatelet therapy (DAPT) and stent
thrombosis after cessation of DAPT is the main problem. In staged operations, the
cardiac procedure was performed first and after a recovery period of 2 to 8 weeks,
pulmonary resection was performed<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Disadvantages of the staged approach are complications arising
from the consequent administration of anesthesia, risk of disease progression due to
delayed treatment, patients' anxiety, cost of treatment, hospital stay<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>. On the other hand, simultaneous procedures have a longer
operation time and lead to increased risks of operative bleeding, tissue edema and
immunosuppression due to cardiopulmonary bypass (CPB)<sup>[<xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>Off-pump coronary artery bypass grafting (OPCABG) technique has been gaining
popularity since the last decade, because it does not require CPB. Recently, several
papers showed that simultaneous OPCABG and lung resections may be safe and feasible
in combined CAD and LC<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5</xref>-<xref rid="r8" ref-type="bibr">8</xref>]</sup>. We presented our patients who underwent simultaneous surgery
for concurrent CAD and LC in our clinic.</p></sec><sec sec-type="methods"><title>METHODS</title><p>We retrospectively analyzed patients submitted to simultaneous OPCABG and lung
resection from 2014 to 2018. All patients evaluated preoperatively. Respiratory,
cardiovascular and other systemic assessments were meticulously performed. All LCs
were biopsy-proven and metastatic state was eliminated by positron emission
tomography (PET/CT) and cranial magnetic resonance imaging (MRI). If no suspicious
mediastinal lymph node was detected on chest CT and PET-CT examinations,
preoperative invasive staging was not applied. CAD was evaluated with angiography.
All patients were discussed in our multidisciplinary council before the
operation.</p><p>All patients were operated on electively. CABG was performed at first in 3 patients
and then lung resections. Median sternotomy approach was used in all patients. A
left anterior thoracotomy was accompanied in one. Patients were heparinized (100-200
U/kg) prior to surgery to adjust the activated clotting time (ACT) between 200-400
seconds. The pericardium was opened. In order to slightly twist the heart
counterclockwise and lift it to provide more comfort during the revascularization
procedure, deep suspending sutures were placed to the pericardium, taking care not
to interfere with the hemodynamic stability. Both the saphenous vein and the left
internal mammary artery were prepared as grafts. By suturing the proximal and distal
portions of the coronary artery that were anastomosed with 4-0 Prolene, antegrade
and retrograde blood flow was blocked. If there were ST and T changes in
electrocardiogram (ECG) during the suspension, intracoronary shunt was applied. In
order to ensure a stationary anastomosis site, the Octopus III coronary stabilizer
was used. After achieving controlled bradycardia via intravenous administration of
selective beta-1 blocker (metoprolol tartrate), distal anastomoses were applied
using 7-0 Prolene suture. In order to provide a blood-free anastomosis site, a
sterile air blower was used. After placing a side clamp in the ascending aorta,
proximal anastomoses were made with 5-0 Prolene suture. Following hemostasis,
heparin neutralization was provided with protamine at a 1:1.3 ratio.</p><p>Selective lymph node dissection (LND) was performed in all patients<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Stations #2R and #4R were
dissected for right upper lobe (RUL) tumor and stations #4, #5 and #6 were dissected
for left upper lobe (LUL) tumors. Stations #7, #8 and #9 were dissected for lower
lobes in both sides. If the intraoperative frozen section study was positive, then
systematic LND was performed. Histopathological examination was performed on all
surgical resection materials. LC staging was made according to international TNM
staging system (primary tumor spread; regional lymph node involvement; intrathoracic
or distant metastasis).</p><p>After discharge, follow-up visits were scheduled at 3, 6, 12, 18 and 24 months and
then every year. All patients were referred to an oncological council after
discharge.</p></sec><sec sec-type="results"><title>RESULTS</title><p>All patients were male, and the mean patient age was 63.3 years (range 55-74). The
main patient complaints were difficulty in breathing, chest pain and palpitations.
Six cases of squamous cell carcinoma, three of adenocarcinoma and one case of large
cell carcinoma were diagnosed. Six patients had single-vessel CAD and four had
two-vessel CAD. Seven patients were in stage 1, two in stage 2 and one in stage 3.
As comorbidity factors, four patients had diabetes mellitus, four hypertension and
one had chronic obstructive pulmonary disease (<xref rid="t1" ref-type="table">Table
1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient demographics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">Age</th><th align="center" rowspan="1" colspan="1">Gender</th><th align="center" rowspan="1" colspan="1">BMI</th><th align="center" rowspan="1" colspan="1">Tumor cell type</th><th align="center" rowspan="1" colspan="1">TNM</th><th align="center" rowspan="1" colspan="1">Stage</th><th align="center" rowspan="1" colspan="1">Comorbidity</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">T1aN0M0</td><td align="center" rowspan="1" colspan="1">Ia</td><td align="center" rowspan="1" colspan="1">HT, COPD</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">T2aN0M0</td><td align="center" rowspan="1" colspan="1">Ib</td><td align="center" rowspan="1" colspan="1">DM</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">T2bN0M0</td><td align="center" rowspan="1" colspan="1">IIa</td><td align="center" rowspan="1" colspan="1">HT</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">Large cell carcinoma</td><td align="center" rowspan="1" colspan="1">T3N0M0</td><td align="center" rowspan="1" colspan="1">IIb</td><td align="center" rowspan="1" colspan="1">-----</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">T1aN0M0</td><td align="center" rowspan="1" colspan="1">Ia</td><td align="center" rowspan="1" colspan="1">DM</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">T1bN0M0</td><td align="center" rowspan="1" colspan="1">Ia</td><td align="center" rowspan="1" colspan="1">DM</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">T2aN2M0</td><td align="center" rowspan="1" colspan="1">IIIa</td><td align="center" rowspan="1" colspan="1">DM, HT</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">T3N1M0</td><td align="center" rowspan="1" colspan="1">IIIa</td><td align="center" rowspan="1" colspan="1">HT</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">T2aN0M0</td><td align="center" rowspan="1" colspan="1">1b</td><td align="center" rowspan="1" colspan="1">-----</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">T1aN0M0</td><td align="center" rowspan="1" colspan="1">Ia</td><td align="center" rowspan="1" colspan="1">-----</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>BMI=body mass index; COPD=chronic obstructive pulmonary disease;
DM=diabetes mellitus; HT=hypertension; M=male</p></fn></table-wrap-foot></table-wrap><p>The mean operation time was 292 (range 241-336) minutes. Median sternotomy was
performed in all cases. An additional anterior thoracotomy was needed in one patient
submitted to left lower lobectomy. Coronary revascularization was performed first in
eight of the 10 cases. Left internal mammary artery (IMA) graft was used in six
patients and saphenous vein graft was used in four patients (<xref rid="t2" ref-type="table">Tables 2</xref> and <xref rid="t3" ref-type="table">3</xref>). The mean
number of red blood cell suspension transfusions was 1.6 (range 0-4). None of the
patients required cardiopulmonary support. Seven patients required inotropic
agents.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Operative data of the patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">Type of lung resection</th><th align="center" rowspan="1" colspan="1">CABG vessel</th><th align="center" rowspan="1" colspan="1">Graft</th><th align="center" rowspan="1" colspan="1">Incision</th><th align="center" rowspan="1" colspan="1">Lung resection</th><th align="center" rowspan="1" colspan="1">Red blood cells suspension (Unit)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">LUL</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">SVG</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">After OPCABG</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">LUL + RULWR</td><td align="center" rowspan="1" colspan="1">Two</td><td align="center" rowspan="1" colspan="1">Left IMA</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">After OPCABG</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">LLL + RULWR</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">SVG</td><td align="center" rowspan="1" colspan="1">Sternotomy + Left anterior thoracotomy</td><td align="center" rowspan="1" colspan="1">Before OPCABG</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">LLL</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">SVG</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">Before OPCABG</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">RUL</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">SVG</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">After OPCABG</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">RLL</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Left IMA</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">After&#x000a0; OPCABG</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">RUL</td><td align="center" rowspan="1" colspan="1">Two</td><td align="center" rowspan="1" colspan="1">Left IMA</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">After OPCABG</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">RP</td><td align="center" rowspan="1" colspan="1">Two</td><td align="center" rowspan="1" colspan="1">Left IMA</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">After OPCABG</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">RUL</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Left IMA</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">After OPCAB</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">LUL</td><td align="center" rowspan="1" colspan="1">Two</td><td align="center" rowspan="1" colspan="1">Left IMA</td><td align="center" rowspan="1" colspan="1">Sternotomy</td><td align="center" rowspan="1" colspan="1">After OPCAB</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>CABG=coronary artery bypass grafting; IMA=internal mammary artery;
LLL=left lower lobectomy; LUL=left upper lobectomy; OPCABG=Off-pump
coronary artery bypass grafting; RLL=right lower lobectomy; RP=right
pneumonectomy; RUL=left upper lobectomy; RULWR=right upper lobe wedge
resection; SVG=saphenous vein graft</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Revascularization characteristics of the patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">CABG vessel</th><th align="center" rowspan="1" colspan="1">Location</th><th align="center" rowspan="1" colspan="1">Graft</th><th align="center" rowspan="1" colspan="1">Anastomosis technique</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Single&#x000a0;</td><td align="center" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1">SVG</td><td align="center" rowspan="1" colspan="1">End-to-side</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Two</td><td align="center" rowspan="1" colspan="1">LAD and D1</td><td align="center" rowspan="1" colspan="1">LIMA</td><td align="center" rowspan="1" colspan="1">Sequential technique (D1 &#x02013; Side-to-side) (LAD &#x02013;
End-to-side)</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1">SVG</td><td align="center" rowspan="1" colspan="1">End-to-side</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Single&#x000a0;</td><td align="center" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1">SVG</td><td align="center" rowspan="1" colspan="1">End-to-side</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">OM1</td><td align="center" rowspan="1" colspan="1">SVG</td><td align="center" rowspan="1" colspan="1">End-to-side</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1">LIMA</td><td align="center" rowspan="1" colspan="1">End-to-side</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Two</td><td align="center" rowspan="1" colspan="1">LAD and D1</td><td align="center" rowspan="1" colspan="1">LIMA</td><td align="center" rowspan="1" colspan="1">Sequential technique (D1 &#x02013; Side-to-side) (LAD &#x02013;
End-to-side)</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Two</td><td align="center" rowspan="1" colspan="1">LAD and D1</td><td align="center" rowspan="1" colspan="1">LIMA</td><td align="center" rowspan="1" colspan="1">Sequential technique (D1 &#x02013; Side-to-side) (LAD &#x02013;
End-to-side)</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1">LIMA</td><td align="center" rowspan="1" colspan="1">End-to-side</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Two</td><td align="center" rowspan="1" colspan="1">LAD and D1</td><td align="center" rowspan="1" colspan="1">LIMA</td><td align="center" rowspan="1" colspan="1">Sequential technique (D1 &#x02013; Side-to-side) (LAD &#x02013;
End-to-side)</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CABG=coronary artery bypass grafting; LAD=left anterior descending
artery; D1=first diagonal arterial branch of LAD; LIMA=left internal
mammary artery; SVG=saphenous vein graft; OM1=obtuse marginal artery</p></fn></table-wrap-foot></table-wrap><p>One right pneumonectomy, three right upper lobectomies, one right lower lobectomy,
three left upper lobectomies, and two left lower lobectomies were performed.
Additional RUL wedge resections were made for suspicious nodules in the
contralateral lung in two patients. Intraoperative frozen section examination
indicated benign lesions. No N2 disease was detected by selective LND
intraoperatively.</p><p>The mean intensive care length of stay was 3.9 days (range 4-7). The mean hospital
length of stay was 14.4 days (range 5-19). None of the patients required CPB. We saw
four major complications in patients. Bleeding requiring reoperation was seen in one
patient. Another patient had perioperative tension pneumothorax. We opened the
contralateral pleura and introduced a chest tube at the time of closure. One patient
suffered from atrial fibrillation on the second day and recovered with
antiarrhythmic medication. The last patient presented acute respiratory distress
syndrome (ARDS) at the early postoperative period and died due to multiple organ
failure 5 days after the operation. Perioperative or postoperative myocardial
infarction was not seen. The mean duration of postoperative follow-up was 19.1
months (range 6-35). One patient died in the 35<sup>th</sup> month of follow-up of
tumor dissemination (<xref rid="t4" ref-type="table">Table 4</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Postoperative results.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">ICU stay (days)</th><th align="center" rowspan="1" colspan="1">Hospital stay (days)</th><th align="center" rowspan="1" colspan="1">Complication</th><th align="center" rowspan="1" colspan="1">Mortality</th><th align="center" rowspan="1" colspan="1">Survival</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">-----</td><td align="center" rowspan="1" colspan="1">Dead</td><td align="center" rowspan="1" colspan="1">35 months</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">ARDS, multiorgan failure</td><td align="center" rowspan="1" colspan="1">Dead</td><td align="center" rowspan="1" colspan="1">5 day</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">-----</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">30 months</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">-----</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">6 months</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">Reoperation for bleeding</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">28 months</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">-----</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">27 months</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">-----</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">25 months</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">Perioperative tension pneumothorax</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">20 months</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">-----</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">6 months</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">9 months</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>ARDS=adult respiratory distress syndrome; ICU=intensive care unit</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In combined CAD and LC, treatment options are: 1) PCI followed by lung resection; 2)
staged CABG and lung resection; 3) simultaneous CABG and lung resection<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. CABG can be performed with or
without CPB. Regarding the treatment of these patients, each technique has its own
advantages and disadvantages.</p><p>Balloon angioplasty with stent placement is a safe and effective method, but it has
not been recommended for patients with left main CAD and with three-vessel disease.
It has increased risk of operative bleeding related to the use of antithrombotic
medication<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Timing of cancer surgery is debatable due to stent
thrombosis after cessation of DAPT. At least, 3 month delay between PCI and lung
resection has been recommended<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Fernandez et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> showed increased perioperative
thrombosis or myocardial infarction and mortality in patients with stents compared
to non-stent patients. Stent placement in the 12 months prior to surgery
significantly increased 30-day cardiac events (9.3%) and mortality (7.7%).</p><p>The use of CPB in CABG is still a great dilemma due to its side effects such as:
increased surgical bleeding, triggering the systemic inflammatory response syndrome;
increased capillary bed permeability; and pulmonary edema, leading to impairment in
immune system<sup>[<xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r6" ref-type="bibr">6</xref>]</sup>. The purpose of the OPCABG is to protect
physiological systems from adverse effects resulting from the use of CPB and related
methods. Performing myocardial revascularization while the heart is still beating
helps to reduce postoperative complications and immunosuppression<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Avoidance of CPB results in
reduced pulmonary function disturbances, decreased incidence of postoperative atrial
fibrillation, and reduced need for blood transfusion, perioperative intra-aortic
balloon pump and possible tumor cell dissemination<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>Patients undergoing simultaneous surgery with CPB present complications and mortality
rates significantly higher than those expected in staged procedures<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Bleeding rate is between 0-16%<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> and the infectious complications are about
14%<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> in CPB used in
simultaneous surgery. Operative mortality, 1- and 5-year survival were 0-20.8%,
79-100% and 34.9-85%, respectively, in patients undergoing simultaneous surgery,
while 0-10%, 72.7% and 53%, respectively, in patients undergoing staged
surgery<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5</xref>]</sup>. On the other hand, OPCABG has been shown to be a
safe and reliable method for simultaneous surgery<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5</xref>-<xref rid="r8" ref-type="bibr">8</xref>]</sup>(<xref rid="t5" ref-type="table">Table 5</xref>). Bleeding risk and mortality ranged from 0 to 8% and 0 to 6.6%,
respectively. Five-year survival was 13 to 68%<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5</xref>]</sup>. In our patients,
bleeding rate and operative mortality occur in one (10%) patient.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Outcomes of simultaneous OPCABG and lung tumor resection in the
literature.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">Author, study</th><th align="center" valign="top" rowspan="1" colspan="1">Outcomes</th><th align="center" valign="top" rowspan="1" colspan="1">Conclusion</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Saxena et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup><break/> &#x02022;
Cohort study (2004) <break/> &#x02022; Six patients underwent OPCABG
and LR between 2000-2004<break/> &#x02022; Mean age was 67.6 years
(58-75) <break/> &#x02022; Single- to 3-vessel CAD and stage 1-2
tumors</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Patients were followed up for 9
months to 3 years <break/> &#x02022; Prolonged airleak and pleural
space in 2 patients <break/> &#x02022; No CAD recurrence <break/>
&#x02022; No early mortality<break/> &#x02022; Late mortality: 2/6
patients (33%)<break/> &#x02022; Mean hospital stay: 12.5 days</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Authors concluded that combined
surgery is a safe approach in patients with concomitant CAD and lung
cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Schoenmakers et al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup><break/> &#x02022;
Cohort study (2007) <break/> &#x02022; 28 patients underwent CABG and
15 underwent OPCABG and LR between 1994-2005 <break/> &#x02022; Mean
age was 66 years in CABG group and 71 years in OPCABG group<break/>
&#x02022; Single- to 3-vessel CAD and stage 1-3 tumors</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Hospital mortality was 2% in CABG
and 1% in OPCABG group (<italic>P</italic>&#x0003c;0.05).<break/>
&#x02022; Reexploration, cardiac and pulmonary complications.
<break/> &#x02022; There were more pulmonary complications in the
CABG group ( <italic>P</italic>=0.04). <break/> &#x02022; Mean
survival was 5.25 years in CABG group and 3 years in OPCABG group
(<italic>P</italic>=0.09) <break/> &#x02022; Two- and 5-year
survival rates are 64% and 46% in CABG group and 47% and 13% in
OPCABG group ( <italic>P</italic>&#x0003c;0.01).<break/> &#x02022; Mean
hospital stay was 14 days in CABG group and 12 days in OPCABG
group</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Authors believe that the results
of their study did not show evidence that OPCABG is a superior
treatment to CABG in patients with combined cardiac and lung
pathology<break/> &#x02022; On the other hand, OPCABG group has fewer
and older patients. And they have more advanced lung cancer,
therefore more studies were needed for evaluation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Dyszkiewicz et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>
<break/> &#x02022; Cohort study (2008) <break/> &#x02022; 25 patients
underwent combined OPCABG and LR from 2001 to 2006 <break/> &#x02022;
Mean age was 63 years (57-75)<break/> &#x02022; Majority of patients
have 2-vessel CAD and stage 1-3 tumors <break/> &#x02022; 13 patients
had undergone PCI and/or stent implantation before lung cancer was
diagnosed</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Patients were followed up for 8
months to 5 years <break/> &#x02022; No perioperative death and new
MI<break/> &#x02022; Rethoracotomy in 1 patient, atrial fibrillation
in 6, atelectasis in 3, prolonged airleak in 3, bronchopleural
fistula in 1<break/> &#x02022; 3-year survival was 50%<break/>
&#x02022; Recurrence of cancer was 55% and was the only statistically
significant factor with an impact on survival
(<italic>P</italic>&#x0003c;0.01) <break/> &#x02022; Mean hospital stay
was 8 days (6-28)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Combined surgery is a safe and
effective treatment in patients with concomitant unstable CAD and
lung cancer<break/> &#x02022; According to the author, combined
surgery requires different surgical skills</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Ma et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup><break/> &#x02022;
Cohort study (2016) <break/> &#x02022; 34 patient underwent combined
OPCABG and LR from 2003 to 2014<break/> &#x02022; Mean age was 65
years (54-77) First OPCABG was performed and then LR<break/>
&#x02022; Single- to 3-vessel CAD and stage 1-3 lung cancer
patients</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Patients were followed up for 5
to 60 months<break/> &#x02022; No perioperative death<break/>
&#x02022; No perioperative MI<break/> &#x02022; Two patients had lung
infection, 3 had atelectasis and 5 had arrhythmias <break/> &#x02022;
Three- and 5-year mortality were 75 and 67%, respectively <break/>
&#x02022; Recurrence occured in 7 patients <break/> &#x02022; Mean
hospital stay was 17&#x000b1;6 days</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Combined OPCABG and LR is a safe
and effective treatment option with good long-term survival rates
<break/> &#x02022; Additionally, this procedure is a safe option in
patients with 3-vessel CAD who are not candidates for PCI</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Yeginsu et al. (present
article)<break/> &#x02022; Cohort study (current)<break/> &#x02022; 10
patients underwent combined OPCABG and LR from 2014 to 2018<break/>
&#x02022; Mean age was 63 (55-74) years <break/> &#x02022;Single to 2
vessel CAD and stage 1-2 lung cancer patients&#x000a0;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Patients were followed up for 6
to 35 months <break/> &#x02022; No operative death <break/> &#x02022;
No operative MI <break/> &#x02022; One patient (10%) died in early
and 1 (10%) died in the late postoperative period<break/> &#x02022;
Major complications were bleeding, ARDS, tension pneumothorax and
atrial fibrillation<break/> &#x02022; Mean hospital stay was 14.4
days (5-19)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Combined OPCABG and LR is a safe
and reliable surgical method; however, data is not sufficient to
conclude that it is the best approach for the patient with
concomitant CAD and lung cancer</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>ARDS=adult respiratory distress syndrome; CABG=coronary artery bypass
grafting; CAD=coronary artery disease; OPCABG=off-pump coronary artery
bypass grafting; LR=lung resection; MI=myocardial infarction;
PCI=percutaneous coronary intervention</p></fn></table-wrap-foot></table-wrap><p>In technical aspects of simultaneous operations, choice of procedural approach,
timing and sequence of surgical steps, and adequacy of procedure for tumor surgery
are important issues.</p><p>Median sternotomy should be the standard approach for simultaneous heart and lung
operations<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Compared to posterolateral thoracotomy, pulmonary dysfunction
and postoperative pain are lower with median sternotomy. However, sternotomy may be
inefficient to provide an adequate field of vision for lung resections. The process
of dissection and traction of the heart may lead to arrhythmias and hemodynamic
instability, especially for tumors localized to left lower lobe. By opening the
right pleura and pericardium and pushing the heart to the right side, a better field
of vision may be accomplished. Single-lung ventilation, complete mobilization of the
lung and myocardial revascularization in the first place may facilitate this
maneuver<sup>[<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. An additional left anterior
thoracotomy and/or thoracoscopic assistance are very helpful for an adequate
exposure. We performed sternotomy plus anterior thoracotomy in one patient with left
lower lobe tumor and we found no difficulty during resection.</p><p>The main goal of a simultaneous operation in patients with lung tumor and CAD should
be to avoid myocardial ischemia during lung resection. Therefore, OPCABG should be
performed first rationally<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.
However, it is recommended that lung resection should be performed first when CPB is
used<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. In addition, some
technical difficulties, such as tumor size and location, dense pleural adhesions,
use of both IMAs, may require lung resection first. We performed lung resection
first in two patients because the tumors located centrally in left lower lobe and
there were dense pleural adhesions and we concerned about injuring the grafts when
we resected the lobes.</p><p>Another important aspect in LC surgery with median sternotomy is the adequate
dissection of mediastinal and hilar lymph nodes. Single-lung ventilation, dividing
inferior pulmonary ligament and intrapleural liberation, may help to achieve an
adequate field of vision for LND. With sternotomy, hilar, interlobar, lobar,
segmental and inferior pulmonary lymph nodes at both mediastinal, and subcarinal
lymph nodes on the left side may be sampled<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Although systematic LND is recommended<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, selective LND is also an
acceptable option in LC surgery for adequate tumor cleaning and staging for stage 1
and 2 tumors<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. The reported
possible advantage of selective LND is reducing the hospital stay, but its
reliability and applicability are still unclear. Multi-institutional randomized
clinical trials are needed to answer the question of which is the best option.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, simultaneous lung resections and OPCABG in patients with CAD
accompanying LC is a safe and reliable surgical method. Several authors reported
that it presented less morbidity and mortality compared to other options using CPB.
Long-term survival is comparable in the others. On the other hand, data are not
sufficient to conclude that combined OPCABG and lung resection are the best approach
for the patient with concomitant LC and CAD. We need larger randomized studies for
certainty.</p><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AY</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">MV</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">BCK</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">AE</td><td align="left" rowspan="1" colspan="1">Final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">AET</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">FB</td><td align="left" rowspan="1" colspan="1">Final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">EG</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">CAK</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Kartal Kosuyolu Yuksek Ihtisas Training and
Research Hospital, Kartal, Istanbul, Turkey.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozower</surname><given-names>BD</given-names></name><name><surname>Sheng</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>S</given-names></name><name><surname>O'Brien</surname><given-names>SM</given-names></name><name><surname>Liptay</surname><given-names>MJ</given-names></name><name><surname>Lau</surname><given-names>CL</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><etal/></person-group><article-title>STS database risk models: predictors of mortality and major
morbidity for lung cancer resection</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>90</volume><issue>3</issue><fpage>875</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">20732512</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyszkiewicz</surname><given-names>W</given-names></name><name><surname>Jemielity</surname><given-names>M</given-names></name><name><surname>Piwkowski</surname><given-names>C</given-names></name><name><surname>Kasprzyk</surname><given-names>M</given-names></name><name><surname>Perek</surname><given-names>B</given-names></name><name><surname>Gasiorowski</surname><given-names>L</given-names></name><etal/></person-group><article-title>The early and late results of combined off-pump coronary artery
bypass grafting and pulmonary resection in patients with concomitant lung
cancer and unstable coronary heart disease</article-title><source>Eur J Cardiothorac Surg</source><year>2008</year><volume>34</volume><issue>3</issue><fpage>531</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">18583144</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>B</given-names></name><name><surname>Bolton</surname><given-names>WD</given-names></name></person-group><article-title>Management of lung cancer with concomitant cardiac
disease</article-title><source>Thorac Surg Clin</source><year>2018</year><volume>28</volume><issue>1</issue><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">29150039</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urschel</surname><given-names>HC Jr</given-names></name><name><surname>Razzuk</surname><given-names>MA</given-names></name></person-group><article-title>Median sternotomy as a standard approach for pulmonary
resection</article-title><source>Ann Thorac Surg</source><year>1986</year><volume>41</volume><issue>2</issue><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">3947162</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tourmousoglou</surname><given-names>CE</given-names></name><name><surname>Apostolakis</surname><given-names>E</given-names></name><name><surname>Dougenis</surname><given-names>D</given-names></name></person-group><article-title>Simultaneous occurrence of coronary artery disease and lung
cancer: what is the best surgical treatment strategy?</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2014</year><volume>19</volume><issue>4</issue><fpage>673</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">25002274</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenmakers</surname><given-names>MC</given-names></name><name><surname>Boven</surname><given-names>WJ van</given-names></name><name><surname>Bosch</surname><given-names>J van den</given-names></name><name><surname>Swieten</surname><given-names>HA van</given-names></name></person-group><article-title>Comparison of on-pump or off-pump coronary artery
revascularization with lung resection</article-title><source>Ann Thorac Surg</source><year>2007</year><volume>84</volume><issue>2</issue><fpage>504</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">17643624</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Ou</surname><given-names>S</given-names></name></person-group><article-title>Lung cancer resection with concurrent off-pump coronary artery
bypasses: safety and efficiency</article-title><source>J Thorac Dis</source><year>2016</year><volume>8</volume><issue>8</issue><fpage>2038</fpage><lpage>2045</lpage><pub-id pub-id-type="pmid">27621857</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>P</given-names></name><name><surname>Tam</surname><given-names>RK</given-names></name></person-group><article-title>Combined off-pump coronary artery bypass surgery and pulmonary
resection</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>78</volume><issue>2</issue><fpage>498</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">15276505</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>Selective lymph node dissection in early-stage non-small cell
lung cancer</article-title><source>J Thorac Dis</source><year>2017</year><volume>9</volume><issue>7</issue><fpage>2102</fpage><lpage>2107</lpage><pub-id pub-id-type="pmid">28840011</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>JM</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>JF</given-names></name><name><surname>Tenas</surname><given-names>MS</given-names></name><name><surname>Ruig&#x000f3;mez</surname><given-names>JG</given-names></name></person-group><article-title>Update on interventional cardiology</article-title><source>Rev Esp Cardiol</source><year>2012</year><volume>65</volume><issue>Suppl 1</issue><fpage>4</fpage><lpage>11</lpage></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaluza</surname><given-names>GL</given-names></name><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JR</given-names></name><name><surname>Raizner</surname><given-names>ME</given-names></name><name><surname>Raizner</surname><given-names>AE</given-names></name></person-group><article-title>Catastrophic outcomes of noncardiac surgery soon after coronary
stenting</article-title><source>J Am Coll Cardiol</source><year>2000</year><volume>35</volume><issue>5</issue><fpage>1288</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">10758971</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chassot</surname><given-names>PG</given-names></name><name><surname>Delabays</surname><given-names>A</given-names></name><name><surname>Spahn</surname><given-names>DR</given-names></name></person-group><article-title>Preoperative evaluation of patients with, or at risk of, coronary
artery disease undergoing non-cardiac surgery</article-title><source>Br J Anaesth</source><year>2002</year><volume>89</volume><issue>5</issue><fpage>747</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">12393774</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>FG</given-names></name><name><surname>Crabtree</surname><given-names>TD</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Meyers</surname><given-names>BF</given-names></name></person-group><article-title>Incremental risk of prior coronary arterial stents for pulmonary
resection</article-title><source>Ann Thorac Surg</source><year>2013</year><volume>95</volume><issue>4</issue><fpage>1212</fpage><lpage>1218</lpage><pub-id pub-id-type="pmid">23465849</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group><article-title>Changes in phospholipase D activity of leukocytes during human
systemic inflammatory response syndrome induced by cardiopulmonary
bypass</article-title><source>Chin Med J</source><year>2003</year><volume>116</volume><issue>6</issue><fpage>873</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">12877798</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>S</given-names></name><name><surname>Otake</surname><given-names>Y</given-names></name><name><surname>Bando</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Inui</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name></person-group><article-title>Pulmonary dissemination of tumor cells after extended resection
of thyroid carcinoma with cardiopulmonary bypass</article-title><source>J Thorac Cardiovasc Surg</source><year>2002</year><volume>124</volume><issue>3</issue><fpage>635</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">12202885</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patan&#x000e8;</surname><given-names>F</given-names></name><name><surname>Verzini</surname><given-names>A</given-names></name><name><surname>Zingarelli</surname><given-names>E</given-names></name><name><surname>Summa</surname><given-names>M di</given-names></name></person-group><article-title>Simultaneous operation for cardiac disease and lung
cancer</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2002</year><volume>1</volume><issue>2</issue><fpage>69</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17669963</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivi&#x000e8;re</surname><given-names>A Brutel de la</given-names></name><name><surname>Knaepen</surname><given-names>P</given-names></name><name><surname>Swieten</surname><given-names>H Van</given-names></name><name><surname>Vanderschueren</surname><given-names>R</given-names></name><name><surname>Ernst</surname><given-names>J</given-names></name><name><surname>Bosch</surname><given-names>J Van den</given-names></name></person-group><article-title>Concomitant open heart surgery and pulmonary resection for lung
cancer</article-title><source>Eur J Cardiothorac Surg</source><year>1995</year><volume>9</volume><issue>6</issue><fpage>310</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">7546803</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tschernko</surname><given-names>EM</given-names></name><name><surname>Bambazek</surname><given-names>A</given-names></name><name><surname>Wisser</surname><given-names>W</given-names></name><name><surname>Partik</surname><given-names>B</given-names></name><name><surname>Jantsch</surname><given-names>U</given-names></name><name><surname>Kubin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Intrapulmonary shunt after cardiopulmonary bypass: the use of
vital capacity maneuvers versus off-pump coronary artery bypass
grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>2002</year><volume>124</volume><issue>4</issue><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">12324731</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleveland</surname><given-names>JC Jr</given-names></name><name><surname>Shroyer</surname><given-names>AL</given-names></name><name><surname>Chen</surname><given-names>AY</given-names></name><name><surname>Peterson</surname><given-names>E</given-names></name><name><surname>Grover</surname><given-names>FL</given-names></name></person-group><article-title>Off-pump coronary artery bypass grafting decreases risk-adjusted
mortality and morbidity</article-title><source>Ann Thorac Surg</source><year>2001</year><volume>72</volume><issue>4</issue><fpage>1282</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">11603449</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howington</surname><given-names>JA</given-names></name><name><surname>Blum</surname><given-names>MG</given-names></name><name><surname>Chang</surname><given-names>AC</given-names></name><name><surname>Balekian</surname><given-names>AA</given-names></name><name><surname>Murthy</surname><given-names>SC</given-names></name></person-group><article-title>Treatment of stage I and II non-small cell lung cancer: Diagnosis
and management of lung cancer, 3rd ed: American College of Chest Physicians
evidence-based clinical practice guidelines</article-title><source>Chest</source><year>2013</year><volume>143</volume><issue>5</issue><supplement>Suppl</supplement><fpage>e278S</fpage><lpage>e313S</lpage><pub-id pub-id-type="pmid">23649443</pub-id></element-citation></ref></ref-list></back></article>